Tekla Life Sciences Investors (HQL) wird mit einem nachlaufenden KGV von gehandelt 5.8. Die nachlaufende Gewinnrendite beträgt 17.27%. Die Graham-Zahl beträgt $34.45.
Durch diese Seite bewiesene Kriterien:
SharesGrow Gesamtbewertung: 86/100 mit 4/7 Kriterien bestanden.
| Year | P/E (TTM) | PEG-Verhältnis | P/B-Verhältnis | P/S-Verhältnis | Dividendenrendite |
|---|---|---|---|---|---|
| 2016 | -18.7 | 0.36 | 0.54 | 35.46 | 15.22% |
| 2017 | 6.7 | 0.03 | 0.98 | 6.57 | 7.40% |
| 2018 | 15.9 | -0.26 | 0.96 | 229.61 | 8.01% |
| 2019 | -5.0 | 0.01 | 0.91 | 143.42 | 9.87% |
| 2020 | 3.4 | -0.01 | 0.87 | 10.73 | 8.36% |
| 2021 | 7.8 | -0.16 | 0.96 | 11.21 | 8.13% |
| 2022 | -3.4 | 0.01 | 0.88 | 11.01 | 10.76% |
| 2023 | 15.8 | -0.13 | 0.88 | 8.96 | 10.26% |
| 2024 | 5.0 | 0.02 | 0.92 | 4.88 | 11.01% |
| 2025 | 5.2 | -1.99 | 0.87 | 5.18 | 7.06% |
| Year | EPS (verwässert) | Umsatz | Nettogewinn | Nettomarge |
|---|---|---|---|---|
| 2016 | $-0.57 | $6.29M | $-11.91M | -189.3% |
| 2017 | $3.21 | $69.81M | $68.56M | 98.2% |
| 2018 | $1.28 | $1.99M | $28.66M | 1443.4% |
| 2019 | $-3.04 | $2.44M | $-70.48M | -2887.8% |
| 2020 | $5.16 | $124.08M | $123.05M | 99.2% |
| 2021 | $2.66 | $65.69M | $64.53M | 98.2% |
| 2022 | $-4.07 | $-103.25M | $-104.6M | - |
| 2023 | $0.79 | $23.52M | $22.35M | 95% |
| 2024 | $3.04 | $86.69M | $85.3M | 98.4% |
| 2025 | $2.96 | $86.39M | $85.59M | 99.1% |
